ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT

ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT MEASURED BY BIOIMPEDANCE IN TYPE 2 DIABETES PATIENTS. Pilot Study.

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05032001

Enrollment

Registered

2021-09-02

Start date

2021-08-01

Completion date

2022-08-01

Last updated

2021-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal Obesity, Type 2 Diabetes

Brief summary

Weight control is an essential part of treatment for type 2 diabetes (T2D) patients. Weight loss is associated with decreased haemoglobin A1c (A1c) levels. In particular, visceral fat is accompanied by more alterations in glucose and lipid metabolism. Quantification of visceral fat with bioimpedance (BIA) is closely related to measurement with computed axial tomography. Different available oral antidiabetics cause weight loss and total body fat (biguanides, DPP-4 inhibitors and SGLT-2 inhibitors), but it has only been shown that SLGT2 inhibitors decrease visceral fat. Therefore, the aim of this study is to determine whether there is a difference in the amount of visceral fat measured with BIA in T2D patients between three oral antidiabetic regimens after twelve weeks of treatment, to compare the effect on visceral fat between metformin, DPP4 inhibitors and SGLT2 inhibitors.

Interventions

DRUGBiguanide, DPP4 inhibitors, SGLT2 inhibitors

Oral antidiabetic treatment during twelve weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients +18 years * Patients with visceral fat quantification by BIA at baseline and week twelve * Patients with body mass index \>25 * Patients can swallow tablets

Exclusion criteria

* Patients treated with other oral antidiabetic agents or insulin * Glomerular filtration rate less than 30 mL/min * Transaminemia greater than 2 times the upper reference value * Pregnancy * Malnutrition

Design outcomes

Primary

Measure	Time frame	Description
Change from baseline in visceral fat measured by bioimpedance in kg at weet twelve	Baseline and week twelve	Bioimpedance is a confident method to measured visceral fat

Other

Measure	Time frame	Description
Change from baseline in A1c level at week twelve	Baseline and week twelve	Glycated hemoglobin percentage is the most reliable method to explain glycemic control in type 2 diabetes patients

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026